OptiNose presents phase-III data from Chronic Rhinosinusitis study

Data show significant improvement in symptoms

September 16, 2016
 
Data from two Phase 3 trials were presented for the first time today at the American Rhinologic Society’s Annual Meeting

Data show significant improvement in both subjective symptoms and objective signs of disease with use of the Exhalation Delivery System for Fluticasone (EDS-FLU) in the studied populations

Patients with nasal polyps at baseline experienced significant reduction in polyp grade

EDS-FLU treatment produced significant improvements in all of the four core symptoms of CRS, a broad range of objective and subjective outcome measures, and quality of life

SAN DIEGO — Sept. 16, 2016 —OptiNose, a privately held specialty biopharmaceutical company, today presented data from two phase 3 trials investigating the clinical efficacy and safety of the Company’s novel Exhalation Delivery Systems (EDS) in patients with Chronic Rhinosinusitis (CRS) with and without nasal polyps (the former also referred to simply as “Nasal Polyposis”).  The findings were presented at the American Rhinologic Society’s Annual Meeting in San Diego, CA.

See full press release here